Breast cancer is the most widely recognized cancer in women worldwide and it is the main source of cancer demise in less created nations. Dyslipidemia in breast cancer patients has been considered as a hazard factor for cardiovascular diseases. Tamoxifen is basically hostile to estrogenic and its estrogenic action is fundamentally liable for the adjustments in lipid parameters. Investigation of lipid profiles among breast cancer patients treated with tamoxifen has not been acted in Ethiopia. This examination expected to assess and think about serum lipid profiles between recently analyzed and tamoxifen-treated breast cancer patients. The comparative cross-sectional study design was utilized to decide fasting serum lipid profiles among ladies with breast cancer. Comfort testing strategy was applied to enroll study subjects and 52 breast cancer patients with tamoxifen treatment for a quarter of a year or more and 51 recently analyzed breast cancer patients without treatment were incorporated and serum lipid parameters (TG, TC, HDL-C, and LDL-C) were estimated. In patients accepting tamoxifen, the mean serum TC and LDL-C levels were fundamentally diminished joined by an immaterial rise of HDL-C contrasted with those with no treatment. Lipid profile is altogether enhanced tamoxifen treatment and this affirms tamoxifen assumes cardioprotective jobs in patients under treatment.
Keywords: Breast cancer, Tamoxifen, lipid profile, Dyslipidemia, Cardiovascular diseases